Scientists are working to reduce these complications with an “engineered live biotherapeutic” that protects the human gut from antibiotics. Researchers at Harvard University’s MIT and Wise Institute for Biologically Inspired Engineering have changed a strain. Lactococcus lactis (A bacterium involved in cheese production) to disrupt part of the antibiotic drug that poses a risk to one’s intestinal health. Their treatment uses a genetically engineered strain of bacteria to prevent this disruption in the cells responsible for the effectiveness of the antibiotic.
According to a Study Published in the journal Nature Biomedical Engineering, biotherapeutics have so far proved successful. After administering both microbial treatment and ampicillin to a group of rats, the researchers found that the treatment reduced intestinal disturbances. Except Negatively affects the effectiveness of ampicillin. Biotherapeutic also helped to prevent the loss of resistance against colonization Clostridioids are hard, Bacteria that often cause diarrhea and other digestive problems during a round of antibiotics. A control group of rats that did not receive biotherapeutic drugs has already suffered a loss of bacterial diversity.
Researchers are now working to set up a clinical study to prove the effectiveness of biotherapeutics in humans. Although patients are often instructed to take probiotics or eat fermented foods while taking antibiotics, such measures are not always sufficient to prevent abdominal pain or yeast infections. Yogurt and kimchi bacteria (as well as probiotic bacteria, despite their large numbers) are susceptible to antibiotics, which exist to cleanse the body from any possible infections. If approved for human use, new biotherapeutic patients can enjoy the benefits of antibiotics without the usual side effects.